# ActoGeniX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actogenix

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.actogenix.com
- Total disclosed funding: $52M
- Latest round: Series B (Apr 25, 2013)
- Investors on record: 9

## About

ActoGeniX is a biopharmaceutical company. It focuses on the development and commercialization of biological drugs in Europe and the United States.

## Funding rounds

- Series B, Apr 25, 2013, $11M — Saffelberg Investments
- Series A, Mar 12, 2009, $11M — Ventech, EQT Life Sciences, Gimv, Aescap Venture, Baekeland Fonds, Biovest, VIB, Biotech Fund Flanders
- Series B, Feb 10, 2009, $17M — Ventech, EQT Life Sciences, Gimv, Aescap Venture, Baekeland Fonds, Biovest, VIB, Biotech Fund Flanders
- Series A, Feb 9, 2007, $5.6M — Ventech, EQT Life Sciences, Gimv, Aescap Venture, Baekeland Fonds
- Series A, Sep 12, 2006, $7.3M — EQT Life Sciences, Gimv, Biotech Fund Flanders
- Seed, Jun 1, 2006 — Gimv, VIB

## Investors

- Gimv (https://capitalatlas.ai/funds/gimv) — Seed, Series A, Series B
- VIB — Seed, Series B, Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- Biotech Fund Flanders — Series A, Series B
- Ventech (https://capitalatlas.ai/funds/ventech) — Series A, Series B
- Aescap Venture (https://capitalatlas.ai/funds/aescap-venture) — Series A, Series B
- Baekeland Fonds (https://capitalatlas.ai/funds/baekeland-fonds) — Series A, Series B
- Biovest — Series B, Series A
- Saffelberg Investments (https://capitalatlas.ai/funds/saffelberg-investments) — Series B